Skip to main content

Gerresheimer AG (GRRMF)

OTC Markets (US) Healthcare Medical - Instruments & SuppliesView data quality →
52.5Fair

ValueMarkers Composite Index

Top 44%#25,205 of 44,707
Overvalued

190% above intrinsic value ($8)

UndervaluedFair ValueOvervalued
Piotroski
5/9
Neutral
Beneish
-2.65
Low Risk
Altman
1.17
Distress
DCF Value
$8
Overvalued
ROIC
2.4%
Low
P/E
25.3
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Gerresheimer AG (GRRMF) — VMCI valuation read

Gerresheimer AG sits at VMCI 53/100, with the Healthcare sector median at 50. That 3-point spread is the first thing to note on GRRMF: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.

Form 4 disclosures on GRRMF are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.

**Investor frame.** The Value read on GRRMF: GRRMF trades at 14.0x earnings, 22% below the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of -0.8x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.

GRRMF fell 0.5% over the trailing 7 days, with a -2.7% read on a 30-day basis.

Gerresheimer AG, together with its subsidiaries, manufactures and sells packaging products, and drug delivery-devices and solutions worldwide. It operates through Plastics & Devices, Primary Packaging Glass, and Advanced Technologies divisions. The Plastics & Devices division offers drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries; containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications; and bottles and containers for nutritional supplements. The Primary Packaging Glass division offers glass primary packaging for pharma and cosmetics industries, such as infusion, dropper, and syrup bottles; injection vials, ampoules, and cartridges; miniature bottles and glass containers for liquid food, spices, and spirits; and packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division develops smart drug delivery systems, such as micro pumps, which are used to self-administer medication for Parkinson's disease or heart failure to pharmaceutical and biotech customers. The company was founded in 1864 and is headquartered in Düsseldorf, Germany.

CEO: Uwe Ferdinand Röehrhoff13,632 employeesDEwww.gerresheimer.com

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in GRRMF’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.